TELA Bio, Inc. (TELA) Announces Fourth Quarter Loss, Exceeds Revenue Estimates

JELA Bio, Inc. (TELA) posted a quarterly loss of $0.59 per share against a Zacks consensus estimate of a loss of $0.54. That compares to a loss of $0.54 per share a year ago. These figures are adjusted for non-recurring items.

This quarterly report represents a profit surprise of -9.26%. A quarter ago, this company was expected to post a loss of $0.52 per share when it actually produced a loss of $0.57, delivering a surprise of -9.62% .

Over the past four quarters, the company has been unable to exceed consensus EPS estimates.

TELA Bio, Inc., which is part of the Zacks Medical – Biomedical and Genetics industry, reported revenue of $8.37 million for the quarter ended December 2021, beating Zacks’ consensus estimate by 6%. That compares to revenues of $5.67 million a year ago. The company has exceeded consensus revenue estimates four times in the past four quarters.

The sustainability of the immediate stock price movement based on recently released numbers and future earnings forecasts will primarily depend on management’s comments on the earnings call.

Shares of TELA Bio, Inc. are down about 2.3% year-to-date versus a -6.4% decline for the S&P 500.

What’s next for TELA Bio, Inc.

As TELA Bio, Inc. has outperformed the market so far this year, the question on investors’ minds is: what’s next for the stock?

There is no easy answer to this key question, but a reliable measure that can help investors answer it is the company’s earnings outlook. This includes not only current consensus earnings expectations for the upcoming quarter(s), but also how those expectations have changed recently.

Empirical research shows a strong correlation between short-term stock movements and trends in earnings estimate revisions. Investors can track these revisions on their own or rely on a proven scoring tool like Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.

Prior to this earnings release, the trend of estimate revisions for TELA Bio, Inc. is mixed. While the magnitude and direction of estimate revisions may change following the release of the company’s earnings report, the current situation translates into a No. 3 (hold) Zacks ranking for the stock. Thus, the shares should move in line with the market in the near future. You can see the full list of today’s Zacks #1 Rank (Strong Buy) stocks here.

It will be interesting to see how the estimates for the next few quarters and the current fiscal year change in the days ahead. The current consensus EPS estimate is -$0.38 on $8.45 million in revenue for the upcoming quarter and -$1.31 on $42.25 million in revenue for the current fiscal year .

Investors should be aware that the outlook for the sector can also have a significant impact on stock performance. In terms of Zacks industry rankings, the medical – biomedical and genetics sector currently sits in the bottom 38% of the more than 250 Zacks industries. Our research shows that the top 50% of industries ranked by Zacks outperform the bottom 50% by a factor of more than 2 to 1.

Another stock in the same sector, Aeterna Zentaris (AEZS), has not yet released its results for the quarter ended December 2021.

The drug developer is expected to post a quarterly loss of $0.02 per share in its upcoming report, which is no change from the year-ago quarter. The consensus EPS estimate for the quarter remained unchanged for the past 30 days.

Aeterna Zentaris revenue is expected to be $0.6 million, down 74.7% from the year-ago quarter.

Breakout biotech stocks with triple-digit profit potential

The biotechnology sector is expected to surpass $2.4 trillion by 2028, with scientists developing treatments for thousands of diseases. They are also finding ways to modify the human genome to literally erase our vulnerability to these diseases.

Zacks just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors take advantage of 7 stocks poised to outperform. Recommendations from previous editions of this report produced gains of +205%, +258% and +477%. Stocks in this report could perform even better.

See these 7 game-changing actions now >>

Click to get this free report

TELA Bio, Inc. (TELA): Free Stock Analysis Report

AEterna Zentaris Inc. (AEZS): Free Stock Analysis Report

To read this article on, click here.

Zacks Investment Research

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


Not all news on the site expresses the point of view of the site, but we transmit this news automatically and translate it through programmatic technology on the site and not from a human editor.


"Writer. Coffee practitioner. Twitter specialist. Food trailblazer. Subtly charming analyst. Troublemaker. Unable to type with boxing gloves on."
Back to top button